Catalyst
Slingshot members are tracking this event:
Gilead (GILD) Expects to Submit New Drug Application for HIV-1 Infection Single Tablet Regimen Bictegravir (B/F/TAF) to FDA in Q3 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| GILD |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 12, 2017
Occurred Source:
http://www.gilead.com/news/press-releases/2017/6/gilead-submits-new-drug-application-to-us-food-and-drug-administration-for-fixeddose-combination-of-bictegravir-emtricitabine-and-tenofovir-alafenamide-for-hiv-treatment
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
New Drug Application, Hiv-1 Infection, Bictegravir, Tenofovir Alafenamide, Emtricitabine, B/f/taf
